A Multicenter Phase II Study of Second‐Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First‐Line Sorafenib Monotherapy

LESSONS LEARNED: For patients with advanced hepatocellular carcinoma after failure of first‐line sorafenib monotherapy, second‐line axitinib provides modest efficacy with tolerable toxicity. The discrepant tumor responses and survival outcomes in trials using axitinib as salvage therapy highlight th...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncologist
Main Authors: Lin, Zhong‐Zhe, Chen, Bang‐Bin, Hung, Yi‐Ping, Huang, Po‐Hsiang, Shen, Ying‐Chun, Shao, Yu‐Yun, Hsu, Chih‐Hung, Cheng, Ann‐Lii, Lee, Rheun‐Chuan, Chao, Yee, Hsu, Chiun
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Inc. 2020
Teme:
Clinical Trial Results
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7485356/
https://ncbi.nlm.nih.gov/pubmed/32271494
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0143
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki